Frederick H. Hausheer, M.D., is the founder, chairman and CEO of BioNumerik Pharmaceuticals,Inc. and co-founder, chairman and CEO of KI Pharma LLC., Japan. He is an adjunct associate professor at The Johns Hopkins Oncology Center and The University of Texas Health Sciences Center at San Antonio, as well as a business advisory board member at JP Morgan Chase Bank. He holds a bachelor’s in biology from Graceland College, a master’s from the University of Illinois in Urbana, and a medical degree from the University of Missouri School of Medicine. Hausheer has co-authored more than 150 medical and scientific research publications and is the inventor or co-inventor on more than 200 U.S. and international patents and patent applications involving new pharmaceutical agents, formulations and methods of use for cancer treatment and other diseases. He talks with the Business Journal about Tavocept, a lung cancer drug BioNumerik has in late-stage clinical development.

Lees meer..

An 11th-hour attempt to extend a key patent could cost companies — including a small East Bay cardiovascular catheter maker — millions in potential revenue.

Lees meer..

KV Pharmaceutical Co. is awaiting an October deadline for federal approval of a drug anticipated to boost company revenue while combating a national health epidemic — preterm births.

Lees meer..

An Emeryville company attempting to tap an Australian weed for a treatment of a precancerous skin condition has landed a new top management team and a $24 million investment after a failed IPO.

Lees meer..

As it looks toward a marriage with Genentech Inc. and South San Francisco, Swiss drug maker Roche is filing for divorce from Palo Alto.

Lees meer..

PolyMedix Inc. received Food and Drug Administration clearance to begin human testing of the company’s experimental anticoagulant reversing agent PMX-60056.

Lees meer..

A quarter century ago when heavy manufacturing — then the lifeblood of Pennsylvania’s economy — was showing signs of terminal decline, state lawmakers and business leaders began searching for remedies to breathe new life into the economic base of the state. The remedy for the technology sector came in the form of the law signed by then-Gov. Richard Thornburgh, creating the Ben Franklin Technology Partners (BFTP) to bring investment capital, entrepreneurial knowledge and the infrastructure to provide the seed funding needed to support tech growth.

Lees meer..

RESEARCH TRIANGLE PARK – The pending $3.1 billion purchase of Talecris Biotherapeutics is not a done deal, and there’s a small but real chance that the deal won’t go through.

Lees meer..

A Georgia legislator wants to examine how the state university system governs its intellectual property — an issue prompted by The University of Georgia Research Foundation Inc.’s dealings with a giant pharmaceutical company.

Lees meer..

Claes Wahlestedt, who heads Scripps Florida’s efforts to develop drugs for diseases of the central nervous system, has launched new company with business consultant and longtime friend Joe Collard.

Lees meer..